Home
About
Overview
Management Team
Board of Directors
Technology
Overview
Posters
Pipeline
Overview
MT-3724
MT-5111
TAK-169
Clinical Trials
Overview
MT-3724 With Lenalidomide for Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma
Active, not recruiting
MT-3724 for Relapsed or Refractory DLBCL
Active, not recruiting
MT-3724 With Gemcitabine and Oxaliplatin for Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma
Active, not recruiting
MT-5111 in HER2-positive Solid Tumors
Recruiting
TAK-169 for Relapsed or Refractory Multiple Myeloma (RRMM)
Recruiting
News & Media
Press Releases
Presentations
Events
Investors
Overview
News & Events
Company Info
Financial Info
Stock Data
SEC Filings
Governance
Email Alerts
Contact
Careers
Financial Information
Investors
Investors
Overview
News & Events
Overview
Press Releases
IR Calendar
Company Info
Overview
Management Team
Presentations
Contacts
FAQ
Financial Info
Overview
Financial Results
Income Statement
Balance Sheet
Cash Flow
Stock Data
Quote
Charts
Historical Data
SEC Filings
Overview
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
Governance
Overview
Board of Directors
Board Committees
Governance Documents
Email Alerts
Financial Info
Overview
Financial Results
Income Statement
Balance Sheet
Cash Flow
Latest Financial Results
FY 2020
Fiscal Year Ended Dec 31, 2020
Earnings Release
PDF
HTML
10-K
Filing
PDF
HTML
XBRL
ZIP
XLS
HTML
Latest 10-K
View HTML
View PDF
Financials
View the latest financials
Balance Sheet
Income Statement
Cash Flow
Email Alerts
Tear Sheet
Contacts
RSS News Feed